Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14261830 | 0.96 | LMNA (0.32) | TDP1DPP4ALDH1A1 | |
| SCHEMBL15901572 | 0.96 | LMNA (0.32) | TDP1DPP4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4307349 | 0.96 | KDM4E (0.30) | DPP4 | |
| SCHEMBL21088215 | 0.90 | TSHR (0.45) | TSHRALDH1A1MEN1GLACYP2C19 | |
| SCHEMBL10045123 | 0.90 | CYP2C19 (0.45) | TSHRALDH1A1MEN1GLACYP2C19 | |
| SCHEMBL3690416 | 0.87 | TSHR (0.43) | TSHRALDH1A1MEN1GLACYP2C19 | |
| SCHEMBL13649902 | 0.87 | CYP2C19 (0.36) | TSHRALDH1A1MEN1GLACYP2C19 | |
| SCHEMBL4305760 | 0.87 | TSHR (0.36) | TSHRTDP1ALDH1A1MEN1GLA | |
| SCHEMBL14262135 | 0.87 | TSHR (0.43) | TSHRALDH1A1MEN1GLACYP2C19 | |
| SCHEMBL25018205 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110590844-A | Preparation method for synthesizing tenofovir alafenamide by two-step method | 江西农业大学 | 2019-12-20 | — | — | CN | claimed |
| CN-110551153-A | Preparation method for synthesizing tenofovir alafenamide by three-step method | UNIV JIANGXI AGRICULTURAL | 2019-12-10 | — | — | CN | claimed |
| WO-2009129371-A1 | CATHEPSIN C INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | WO | claimed |
| US-20090264499-A1 | Cathepsin C Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | claimed |
| CN-118908998-A | Antiviral prodrugs and uses thereof | 上海柯君医药科技有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118184702-A | Antiviral prodrugs and uses thereof | 上海柯君医药科技有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-112839988-B | Nucleating agent, synthetic resin composition containing same, and molded article thereof | 株式会社ADEKA | 2023-06-06 | — | — | CN | disclosed |
| US-20230159841-A1 | MACROMOLECULAR CORROSION (MCIN) INHIBITORS: STRUCTURES, METHODS OF MAKING AND USING THE SAME | POLNOX CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-11578285-B2 | Macromolecular corrosion (McIn) inhibitors: structures, methods of making and using the same | POLNOX CORPORATION (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220402966-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2022-12-22 | — | — | US | disclosed |
| US-11518746-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-12-06 | — | — | US | disclosed |
| US-20220016082-A1 | COMBINATION THERAPIES FOR HIGH AND VERY HIGH RISK MDS | MEI PHARMA, INC. | 2022-01-20 | — | — | US | disclosed |
| US-6066631-A | Chroman derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-05-23 | — | — | US | disclosed |
| WO-2000012492-A1 | BENZOXAZINE DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-03-09 | — | — | WO | disclosed |
| EP-0945445-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
| EP-0934296-A1 | CHROMAN DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998004542-A1 | CHROMAN DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-05 | — | — | WO | disclosed |
| EP-0562832-A1 | Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1993-09-29 | — | — | EP | disclosed |
| US-4468526-A | Process for the preparation of thiuram disulfides | AKZONA INCORPORATED (US) | 1984-08-28 | — | — | US | disclosed |
| US-4459424-A | SECONDARY AMINE, CARBON DISULFIDE, METAL CONTAINING CATALYST | AKZONA INCORPORATED (US) | 1984-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578285-B2 | Macromolecular corrosion (McIn) inhibitors: structures, methods of making and using the same | MB, NCLN, CPN1 | TSHR 4600/4885TDP1 1469/4885DPP4 3618/4885 |
| US-20220402966-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | TSHR 259/4885TDP1 2642/4885DPP4 748/4885 |
| US-20090264499-A1 | Cathepsin C Inhibitors | CTSB, CTSF, CTSG | TSHR 3924/4885TDP1 4117/4885DPP4 732/4885 |
| US-20220016082-A1 | COMBINATION THERAPIES FOR HIGH AND VERY HIGH RISK MDS | DNMT3A, TET2, HDAC8 | TSHR 4237/4885TDP1 366/4885DPP4 2292/4885 |
| US-11518746-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | DUT, DPYD, TYMP | TSHR 4475/4885TDP1 144/4885DPP4 1994/4885 |
| US-20230159841-A1 | MACROMOLECULAR CORROSION (MCIN) INHIBITORS: STRUCTURES, METHODS OF MAKING AND USING THE SAME | MB, NCLN, CPN1 | TSHR 4600/4885TDP1 1469/4885DPP4 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.